Feasibility and efficacy of hypofractionated proton reirradiation for recurrent lung cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: recurrent thoracic tumors
I · Intervention 중재 / 시술
hypofractionated proton therapy for recurrent lung cancer at a single facility
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSION] This study demonstrates the feasibility and efficacy of a hypofractionated course of proton reirradiation for recurrent thoracic tumors. [DATA AVAILABILITY] The data that support the findings of this study are available on request from the corresponding author.
[PURPOSE] The goal of this study is to report the feasibility and outcomes of hypofractionated proton reirradiation in patients with recurrent thoracic tumors.
- 95% CI 78.9-100
- 추적기간 9.0 months
APA
Karp JM, Banson KM, et al. (2025). Feasibility and efficacy of hypofractionated proton reirradiation for recurrent lung cancer.. International journal of particle therapy, 18, 101213. https://doi.org/10.1016/j.ijpt.2025.101213
MLA
Karp JM, et al.. "Feasibility and efficacy of hypofractionated proton reirradiation for recurrent lung cancer.." International journal of particle therapy, vol. 18, 2025, pp. 101213.
PMID
41437963 ↗
Abstract 한글 요약
[PURPOSE] The goal of this study is to report the feasibility and outcomes of hypofractionated proton reirradiation in patients with recurrent thoracic tumors.
[MATERIALS AND METHODS] Data were retrospectively collected for patients who received hypofractionated proton therapy for recurrent lung cancer at a single facility. Proton reirradiation was delivered using a total of 15 fractions. Patient and tumor characteristics, adverse events, and dose-volume histogram parameters were collected and analyzed descriptively. Tumor control and patient survival were analyzed using Kaplan-Meier statistics. Univariate logistic regression was performed to analyze the relationship between dose-volume histogram parameters and acute and late toxicity.
[RESULTS] Thirty-one patients who received thoracic proton reirradiation were included. The median patient age was 71.4. Most patients (77.4%) were treated to a total of 60 Gy (RBE) in 15 fractions and had tumors smaller than 50 cc (64.5%). The median interval between the 2 radiation courses was 21.3 months (2.9-227.1). Twenty-one out of 31 plans (67.7%) successfully reached a target PTV coverage with V95% > 95%. Complete prior plan dosimetric information was available for 19 out of 31 plans. The median value of the equivalent dose in 2 Gy (RBE) fractions (EQD2) from the plan sum for the lung V20 Gy (RBE) was 24.9%, and for the V5 Gy (RBE) was 44.8%. The median follow-up was 9.0 months. One-year local, regional, and distant control were 92.3% (95% CI 78.9-100), 71.1% (95% CI 52.1-97.0), and 80.6% (95% CI 64.6-100), respectively. Only two patients experienced grade 3 or higher acute or late toxicities. Acute esophagitis was associated with the esophagus Dmax ( = .031) and Dmean ( = .041).
[CONCLUSION] This study demonstrates the feasibility and efficacy of a hypofractionated course of proton reirradiation for recurrent thoracic tumors.
[DATA AVAILABILITY] The data that support the findings of this study are available on request from the corresponding author.
[MATERIALS AND METHODS] Data were retrospectively collected for patients who received hypofractionated proton therapy for recurrent lung cancer at a single facility. Proton reirradiation was delivered using a total of 15 fractions. Patient and tumor characteristics, adverse events, and dose-volume histogram parameters were collected and analyzed descriptively. Tumor control and patient survival were analyzed using Kaplan-Meier statistics. Univariate logistic regression was performed to analyze the relationship between dose-volume histogram parameters and acute and late toxicity.
[RESULTS] Thirty-one patients who received thoracic proton reirradiation were included. The median patient age was 71.4. Most patients (77.4%) were treated to a total of 60 Gy (RBE) in 15 fractions and had tumors smaller than 50 cc (64.5%). The median interval between the 2 radiation courses was 21.3 months (2.9-227.1). Twenty-one out of 31 plans (67.7%) successfully reached a target PTV coverage with V95% > 95%. Complete prior plan dosimetric information was available for 19 out of 31 plans. The median value of the equivalent dose in 2 Gy (RBE) fractions (EQD2) from the plan sum for the lung V20 Gy (RBE) was 24.9%, and for the V5 Gy (RBE) was 44.8%. The median follow-up was 9.0 months. One-year local, regional, and distant control were 92.3% (95% CI 78.9-100), 71.1% (95% CI 52.1-97.0), and 80.6% (95% CI 64.6-100), respectively. Only two patients experienced grade 3 or higher acute or late toxicities. Acute esophagitis was associated with the esophagus Dmax ( = .031) and Dmean ( = .041).
[CONCLUSION] This study demonstrates the feasibility and efficacy of a hypofractionated course of proton reirradiation for recurrent thoracic tumors.
[DATA AVAILABILITY] The data that support the findings of this study are available on request from the corresponding author.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Dosimetric comparison of organs at risk in ultra-hypofractionated versus hypofractionated postoperative radiotherapy for early breast cancer: single center clinical study.
- Utilization of radiotherapy and hypofractionated radiotherapy in Japan: long-term trends and the influence of COVID-19 pandemic.
- Optimising Radiotherapy for Prostate Cancer: Comparison of Treatment Schedules and Toxicities.
- Prospective monitoring of the clinical implementation of ultrahypofractionated whole-breast radiotherapy using electronic patient-reported outcome measures.
- Efficacy and tolerability of hypofractionated and dose-boosted radiotherapy for localised prostate cancer: a systematic review and meta-analysis.
- Trends in hypofractionated radiotherapy use among patients with breast or prostate cancer: a multicenter study in Osaka, Japan.